Comparison of Topical Silymarin with Hydroquinone in the Treatment of Melasma

  • Sumaira Abdullah
  • Mahwish Ahmed
  • Mahvish Aftab Khan
  • Tayaba Iqbal
  • Shawana Sharif
  • Farhat Rehman
Keywords: Melasma, Silymarin, Hydroquinone, MASI score

Abstract

Objective: To compare the efficacy and safety of topical silymarin 0.7% with topical hydroquinone 4% in the treatment of melasma.

Place and Duration: This Randomized Controlled Trial was conducted at dermatology OPD of Akbar Niazi Teaching Hospital, Bara Kahu, Islamabad, in a period of one year from April 2020 to April 2021.

Patients and Methods: Female patients having melasma were included in the study. The severity of melasma was assessed using MASI score. Group A was treated with silymarin 0.7% cream and group B was treated with topical hydroquinone 4% cream. Treatment was given for 3 months and was followed up for the next 3 months to observe relapse. Clinical efficacy was assessed in terms of percent reduction in MASI score from baseline.

Results: The mean age in group A (Silymarin 0.7%)  was 35.13 ± 3.87 and in group B (Hydroquinone 4%)  was 34.16 ± 3.90. Epidermal type of melasma was most common (76.8% vs 62.5%) in both groups. There was no significant (p-value < 0.05) difference between both groups after one and two months treatment but mean MASI score of Hydroquinone 4% group (10.59 ± 5.74) become significantly (p-value < 0.05) less than Silymarin 0.7% group (8.20 ± 4.41) after 3 months. Similar (p-value > 0.05) therapeutic response was observed after one and two months treatment but it become significantly better in Hydroquinone 4% group after three months treatment. Significantly, (P-value < 0.05) higher adverse effects were detected in patients treated with hydroquinone. There was no difference (P-value > 0.05) in recurrence rate and patients satisfaction between both groups.

Conclusion: topical silymarin has equal efficacy for the treatment of melasma with comparatively very less adverse effects as compared to hydroquinone.

References

1. Sonthalia S, Sarkar R. Etiopathogenesis of melasma. Melasma: A Monograph. 2015 Apr 5:6.Sonthalia S, Sarkar R. Etiopathogenesis of melasma. Pigment Int 2015 ; 2 : 21-7.
2. Tzouveka E. Epidemiology and Risk Factors of Melasma. Pigmentary Disorders. 2014;S1:002. DOI: 10.4172/2376-0427.S1-002.Tzoureka E. Epidemio;ogy and risk factora of melasma. Pigmentr Disordr. 2014;S1-002.
3. Ogbechie-Godec OA, Elbuluk N. Melasma: an Up-to-Date Comprehensive Review. Dermatol Ther (Heidelb). 2017 Sep;7(3):305-318. doi: 10.1007/s13555-017-0194-1. Oluwatobi A, Ogbechie-Godec and Nada E. Melasma : an up-to-date Comprehensive review. Dermatol Ther 2017;7(3) :305-18.
4. Shankar K, Godse K, Aurangabadkar S, Lahiri K, Mysore V, Ganjoo A, Vedamurty M, Kohli M, Sharad J, Kadhe G, Ahirrao P, Narayanan V, Motlekar SA. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther (Heidelb). 2014 Dec;4(2):165-86. doi: 10.1007/s13555-014-0064-z. Shankar K, Godse K, aurangabadkar S, Lahiri K, Mysore V, Ganjoo A, et al. Evidence based treatment for melasma : Expert opinion and a review. Dermatol Ther. 2014;4(2):165-86.
5. Rodrigues M, Pandya AG. Melasma: clinical diagnosis and management options. Australas J Dermatol. 2015 Aug;56(3):151-63. doi: 10.1111/ajd.12290. Rodrigues M, Pandya AG. Melasma: Clinical diagnosis and management options. Australas J Dermatol. 2015;56(3):151-63.
6. Sarkar R, Gokhale N, Godse K, Ailawadi P, Arya L, Sarma N, et al. Medical Management of Melasma: A Review with Consensus Recommendations by Indian Pigmentary Expert Group. Indian J Dermatol. 2017 Nov-Dec;62(6):558-577. doi: 10.4103/ijd.IJD_489_17. Sarkar R, Gokhale N, Godse K. Medical management of melasma : A review with consensus recommendations by Indian pigmentary expert group. Indian J Dermatol. 2017;62:558-77.
7. Dorjay K, Arif T, Adil M. Silymarin: An interesting modality in dermatological therapeutics. Indian J Dermatol Venereol Leprol. 2018;84(2):238-243. doi: 10.4103/ijdvl.IJDVL_746_16. Dorjay K, Arif T, Adil M. Silymarin: An interesting modality in dermatological therapeutics. Indian J Dermatol Venereol. 2018;84(2):238-43.
8. Nofal A, Ibrahim AM, Nofal E, Gamal N, Osman S. Topical silymarin versus hydroquinone in the treatment of melasma: A comparative study. J Cosmet Dermatol. 2019 Feb;18(1):263-270. doi: 10.1111/jocd.12769. Nofal A, Ibrahim AM, Nofal E, Gamal N, Osman S. Topical silymarin versus hydroquinone in the treatment of melasma: A comparative study. J Cosmet Dermatol. 2019;18(1):263-70.
9. van Raath MI, Chohan S, Wolkerstorfer A, van der Horst CMAM, Limpens J, Huang X, et al. Clinical outcome measures and scoring systems used in prospective studies of port wine stains: A systematic review. PLoS One. 2020 Jul 2;15(7):e0235657. doi: 10.1371/journal.pone.0235657.
10. Hawthorne G, Sansoni J, Hayes L, Marosszeky N, Sansoni E. Measuring patient satisfaction with health care treatment using the Short Assessment of Patient Satisfaction measure delivered superior and robust satisfaction estimates. J Clin Epidemiol. 2014 May;67(5):527-37. doi: 10.1016/j.jclinepi.2013.12.010.
119. Spierings NMK. Melasma: A critical analysis of clinical trials investigating treatment modalities published in the past 10 years. J Cosmet Dermatol. 2020 Jun;19(6):1284-1289. doi: 10.1111/jocd.13182. Spierings NMK. Melasma: A critical analysis of clinical trials investigating treatment modalities published in the past 10 years. J Cosmet Dermatol. 2020;19(6):1284-9.
120. Lee AY. Skin Pigmentation Abnormalities and Their Possible Relationship with Skin Aging. Int J Mol Sci. 2021 Apr 2;22(7):3727. doi: 10.3390/ijms22073727. Lee AY. Skin pigmentation abnormalities and their possible relationship with skin aging. Int J Mol Sci. 2021;22(7):3727.
131. Altaei T. The treatment of melasma by silymarin cream. BMC Dermatol. 2012 Oct 2;12:18. doi: 10.1186/1471-5945-12-18. Altaei T. The treatment of melasma by Silymarin cream. BMC Dermatol. 2012;12:18.
142. Muneeb B, Aamir S. Effectiveness of intra-lesional tranexamic acid in treatment of melisma. J Pak Assoc Dermatol. 2021;31(1):8-14.
153. Choo SJ, Ryoo IJ, Kim YH, Xu GH, Kim WG, Kim KH, Moon SJ, Son ED, Bae K, Yoo ID. Silymarin inhibits melanin synthesis in melanocyte cells. J Pharm Pharmacol. 2009 May;61(5):663-7. doi: 10.1211/jpp/61.05.0016. Choo SJ, Ryoo IJ, Kim YH, Xu GH, Kim WG, Kim KH, et al. Silymarin inhibits melanin synthesis in melanocyte cells. J Pharm Pharmacol. 2009;61(5):663-7.
164. Pazyar N, Yaghoobi R, Zeynalie M, Vala S. Comparison of the efficacy of intradermal injected tranexamic acid vs hydroquinone cream in the treatment of melasma. Clin Cosmet Investig Dermatol. 2019 Feb 14;12:115-122. doi: 10.2147/CCID.S191964. Pazyar N, Yaghoobi R, Zeynalie M, Vala S. Comparison of the efficacy of intradermal injected tranexamic acid vs hydroquinone cream in the treatment of melasma. Clin Cosmet Investig Dermatol. 2019;12:115-22.
15. Altaei T. The treatment of melasma by silymarin cream. BMC Dermatol. 2012;12:18.
176. Elfar NN, El-Maghraby GM. Efficacy of Intradermal Injection of Tranexamic Acid, Topical Silymarin and Glycolic Acid Peeling in Treatment of Melasma: A Comparative Study. J Clin Exp Dermatol Res. 20156;6: 280. DOI: 10.4172/2155-9554.1000280
187. Ashtiani HRA, Dadgar A, Akaberi M. Improvement of Cell Proliferation and Antioxidant Activity of Silymarin in Hair Follicles Dermal Pa21`q pillae Isolated from the Human Scalp: Comparison with Vitamin C Effects. Int J Trichology. 2020 Jul-Aug;12(4):168-175. doi: 10.4103/ijt.ijt_124_19. Ashtiani HRA, Dadgar A, Akaberi M. Improvement of cell proliferation and antioxidant activity of silymarin in hair follicles dermal papillae isolated from the human scalp: comparison with vitamin c effects. Int J Trichol. 2020;12(4):168-75.
1918. Zarif-Yeganeh M, Rastegarpanah M. Clinical Role of Silymarin in Oxidative Stress and Infertility: A Short Review for Pharmacy Practitioners. J Res Pharm Pract. 2019 Dec 27;8(4):181-188. doi: 10.4103/jrpp.JRPP_18_100. Zarif-Yeganeh M, Rastegarpanah M. Clinical role of silymarin in oxidative stress and infertility: a short review for pharmacy practitioners. J Res Pharm Pract. 2019;8(4):181-8.
2019. Banihashemi M, Zabolinejad N, Jaafari MR, Salehi M, Jabari A. Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma. J Cosmet Dermatol. 2015 Sep;14(3):174-7. doi: 10.1111/jocd.12152. Banihashemi M, Zabolinejad N, Jaafari MR, Salehi M, Jabari A. Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma. J cosmet dermatol. 2015;14:174‐7.
20. Elfar NN, EL‐MaghrabyGM. Efficacy of intradermal injection of tranexamic acid, topical silymarin and glycolic acid peeling in treatment of melasma: a comparative study. J Clinical Exp Dermatol Res. 2015;6(280):2.
21. Adalatkhah H, Sadeghi-Bazargani H. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial. Drug Des Devel Ther. 2015 Aug 4;9:4219-25. doi: 10.2147/DDDT.S80713. Adalatkhah H, Sadeghi‐Bazargani H. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial. Drug Des Devel Ther. 2015;4:4219‐25.
Published
2022-03-31
How to Cite
1.
Abdullah S, Ahmed M, Khan M, Iqbal T, Sharif S, Rehman F. Comparison of Topical Silymarin with Hydroquinone in the Treatment of Melasma. JRMC [Internet]. 31Mar.2022 [cited 27May2022];26(1):90-5. Available from: https://journalrmc.com/index.php/JRMC/article/view/1778